141 related articles for article (PubMed ID: 37084252)
1. The paradigm shift in ANCA-associated vasculitis: prime time for the complement targeting.
Quartuccio L; Treppo E; Alberici F
Rheumatology (Oxford); 2023 Aug; 62(8):2633-2634. PubMed ID: 37084252
[No Abstract] [Full Text] [Related]
2. Complement in antineutrophil cytoplasmic antibody-associated vasculitis.
Yuan J; Chen M; Zhao MH
Clin Exp Nephrol; 2013 Oct; 17(5):642-645. PubMed ID: 23180036
[TBL] [Abstract][Full Text] [Related]
3. The Complement System and ANCA Associated Vasculitis in the Era of Anti-Complement Drugs.
Kimoto Y; Horiuchi T
Front Immunol; 2022; 13():926044. PubMed ID: 35812453
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement.
Noone D; Hebert D; Licht C
Pediatr Nephrol; 2018 Jan; 33(1):1-11. PubMed ID: 27596099
[TBL] [Abstract][Full Text] [Related]
5. Which is important in thoracic CT findings: Antineutrophil cytoplasmic antibody (ANCA) subtype or subgroups of ANCA-associated vasculitis?
Durak Ediboğlu E; Karasu Ş; Ekici T; Gerçik Ö; Gümüş C; Akar S
Int J Rheum Dis; 2024 Jan; 27(1):e14891. PubMed ID: 37638741
[No Abstract] [Full Text] [Related]
6. The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis.
Wester Trejo MAC; Trouw LA; Bajema IM
Curr Opin Rheumatol; 2019 Jan; 31(1):3-8. PubMed ID: 30461541
[TBL] [Abstract][Full Text] [Related]
7. Steroid Sparing Therapies for Antineutrophil Cytoplasmic Autoantibodies Associated Vasculitis.
Ramirez MJZ; Vu D; Jain K
Transfus Med Rev; 2022 Oct; 36(4):233-238. PubMed ID: 36207202
[TBL] [Abstract][Full Text] [Related]
8. [The pathogenesis of ANCA-associated vasculitis].
Ishizu A
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(6):491-496. PubMed ID: 28049957
[TBL] [Abstract][Full Text] [Related]
9. Complement in ANCA-associated vasculitis.
Charles Jennette J; Xiao H; Hu P
Semin Nephrol; 2013 Nov; 33(6):557-64. PubMed ID: 24161040
[TBL] [Abstract][Full Text] [Related]
10. Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.
Muto R; Inagaki K; Sato N; Sameshima T; Nagakura Y; Baba S; Kato N; Maruyama S; Akahori T
Intern Med; 2020 Dec; 59(24):3187-3193. PubMed ID: 32788533
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis-based new perspectives of management of ANCA-associated vasculitis.
Sciascia S; Ponticelli C; Roccatello D
Autoimmun Rev; 2022 Mar; 21(3):103030. PubMed ID: 34971805
[TBL] [Abstract][Full Text] [Related]
12. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
13. What Is the Best Maintenance Therapy for ANCA Vasculitis?
Woerner K; Nachman PH
Clin J Am Soc Nephrol; 2021 Dec; 16(12):1906-1908. PubMed ID: 34753816
[No Abstract] [Full Text] [Related]
14. ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing.
Hutton HL; Holdsworth SR; Kitching AR
Semin Nephrol; 2017 Sep; 37(5):418-435. PubMed ID: 28863790
[TBL] [Abstract][Full Text] [Related]
15. Vasculitis: Rituximab: effective in ANCA-associated vasculitis?
Schönermarck U; de Groot K
Nat Rev Nephrol; 2011 Jan; 7(1):6-8. PubMed ID: 21173754
[No Abstract] [Full Text] [Related]
16. ANCA Vasculitis Treatment in the Dialysis Patient: Caution Needed!
Hendren E; Radhakrishnan J
Clin J Am Soc Nephrol; 2021 Nov; 16(11):1617-1619. PubMed ID: 34750158
[No Abstract] [Full Text] [Related]
17. New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis.
Nozaki Y
Front Immunol; 2021; 12():631055. PubMed ID: 33868250
[TBL] [Abstract][Full Text] [Related]
18. Complement system activation in ANCA vasculitis: A translational success story?
Kallenberg CG; Heeringa P
Mol Immunol; 2015 Nov; 68(1):53-6. PubMed ID: 26597208
[TBL] [Abstract][Full Text] [Related]
19. The rise of complement in ANCA-associated vasculitis: from marginal player to target of modern therapy.
Trivioli G; Vaglio A
Clin Exp Immunol; 2020 Dec; 202(3):403-406. PubMed ID: 32946609
[TBL] [Abstract][Full Text] [Related]
20. Glomerular Immune Deposition in MPO-ANCA Associated Glomerulonephritis Is Associated With Poor Renal Survival.
Lin W; Shen C; Zhong Y; Ooi JD; Eggenhuizen P; Zhou YO; Luo H; Huang J; Chen JB; Wu T; Meng T; Xiao Z; Ao X; Peng W; Tang R; Yin H; Xiao X; Zhou Q; Xiao P
Front Immunol; 2021; 12():625672. PubMed ID: 33841408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
